Global Preimplantation Genetic Testing Market 2025 – 2034

Reports Description

As per the Preimplantation Genetic Testing Market analysis conducted by the CMI team, the preimplantation genetic testing market is expected to record a CAGR of 7.93% from 2025 to 2034. In 2025, the market size was USD 936.12 Million. By 2034, the valuation is anticipated to reach USD 1863.7 Million.

Overview

Increased maternal age coupled with declining rates of fertility is driving the growth of the preimplantation genetic testing market, as couples are increasingly considering genetic testing for ascertaining healthy pregnancies. On these grounds, the Society at a Glance 2024 edition did report a marked decline in the fertility rates, especially in economies like Korea, Spain, and Italy. Such economies are witnessing visibly low fertility rates, thereby resulting in an increased pressure on the couples for maximizing their chances of proper pregnancies.

Also, societal acceptance pertaining to genetic testing and assisted reproductive technology (ART) ought to project a sizable expansion in the years to come. In July 2023, Thermo Fisher Scientific introduced the Ion AmpliSeq Polyploidy Kit and Ion ReproSeq PGT-A Kit for preimplantation genetic testing for aneuploidy (PGT-A). The basic objective of these tools was to improve genetic screening in IVF and ICSI (intracytoplasmic sperm injection) procedures.

Key Trends & Drivers

• Declination in Fertility Rates Worldwide

The world is witnessing an incessant declination in fertility, which is primarily driven by urban lifestyles, delayed childbearing, and socioeconomic pressures. In other words, more couples are getting pushed toward assisted reproduction. With a rise in average maternal age, the risk of aneuploidy rises, thereby raising PGT’s clinical utility regarding the identification of unaffected or euploid embryos. IVF labs and fertility clinics are therefore integrating PGT at the initial stage in care pathways for reducing time-to-pregnancy and success per transfer.

What’s trending in the Preimplantation Genetic Testing Market?

Next-generation sequencing is refurbishing preimplantation genetic testing, thereby offering accurate detection of single-gene disorders and chromosomal issues, whereas AI integration expedites embryo analysis. PGT is also moving to HLA typing for stem cell matching. Polygenic embryo screening (PES) uses genome-wide data for predicting risks for complex diseases such as cancer, heart ailments, and diabetes in adults. Also, with 1 out of 6 people facing infertility across the globe, PGT and IVF are deployed to improve success rates and prevent miscarriages.

Key Threats

Higher costs of IVF plus add-on biopsy, logistics, sequencing, and counselling are a major barrier to the adoption of preimplantation genetic testing, especially in the emerging economies. Also, there is inconsistency in coverage. Several plans limit reimbursement regarding clearing the medical conditions such as PGT-SR/PGT-M, thereby inviting uncertainty for clinics and patients. Until wider reimbursement bundle pricing matures, price sensitivity is likely to limit the penetration on the whole.

Opportunities

Non-invasive preimplantation genetic testing (niPGT) does analyze cell-free embryonic DNA from the spent culture media, thereby doing away with risks involved with trophectoderm biopsy and making the workflow easier. niPGT, by reducing the complexity involved in procedures, can broaden testing to risk- and cost-averse patients and also earlier-stage clinics. Lower staffing needs and consumables do create room for higher attach rates and bundled pricing per IVF cycle. Also, as multi-center validation does tighten precision, niPGT is positioned for unlocking demand in both – value and premium segments.

Category Wise Insights

By Procedure

• Preimplantation Genetic Screening

Preimplantation genetic screening (PGS) services are emphasizing detection of chromosomal abnormalities in the embryos. Such services are preferred by the couples who are of advanced reproductive age, the ones undergoing multiple cycles of IVF, and the ones carrying the history of recurrent termination of pregnancy. Plus, a higher number of the IVF procedures that are conducted in the well-versed laboratories enhance the quality of the PSG services.

• Preimplantation Genetic Diagnosis

The preimplantation genetic diagnosis (PGD) segment held over 75% of the market share in 2024 and the scenario is expected to remain unchanged during the forecast period. This is credited to rising awareness amongst the healthcare professionals as well as end-users regarding genetic testing for specified gene mutations. The rising incidences of translocation cases and single-gene diseases, along with next-generation sequencing (NGS) technology’s implementation for genetic testing, are propelling the growth of the preimplantation genetic testing market further. PGD services facilitate examining embryos for identifying specific gene mutations, thereby aiding in the reduction of such diseases in the newborns.

By Product

• Reagents and Consumables

The reagents and consumables segment holds over 50% of the market share and the status quo is expected to remain unchanged during the forecast period. This is owing to increased adoption of PGT in IVF. It has been reported that over 3 million IVF cycles are performed across the globe, which, in turn, result in the occurrence of more than 700,000 deliveries using IVF. Plus, a rise in the use of advanced testing technologies like next-generation sequencing, fluorescent in situ hybridization, and polymerase chain reaction is anticipated to catalyze the market.

• Instruments

The instruments segment holds the second-largest market share. This is due to the market players actively developing testing instruments providing high-precision results. Moreover, the rising number of clinics and hospitals offering IVF services is expected to raise the demand for the advanced instruments meant for performing preimplantation genetic testing (PGT) onsite.

• Software

Software, especially ML and AI, is important for the preimplantation genetic testing market as it helps in improving data analysis, enhancing embryo selection precision (foretelling viability), reducing human errors, automating workflows, and facilitating sophisticated analysis of complicated genetic data from NGS, thereby resulting in better outcomes of IVF, personalized care, and raised efficiency. Advanced analytics do process cell-free DNA from the culture media, thereby reducing the complexity and facilitating the expansion of access to the risk-averse patients.

By Technology

• Next Generation Sequencing (NGS)

The next-generation sequencing (NGS) segment is anticipated to witness the fastest CAGR during the forecast period. This is due to the fact that NGS tests provide superlative precision in comparison with the other methods and are also capable of sequencing huge quantities of DNA within a shorter time span. Plus, technological advancements have widened NGS’ capabilities, thereby facilitating detection of chromosomal abnormalities.

• Polymerase Chain Reaction (PCR)

The polymerase chain reaction (PCR) segment holds more than 40% of the market share. This is credited to the higher level of accuracy offered by PCR tests. PCR does increase the likelihood of generating a huge number of copies of specified genome segments, thereby improving detection of abnormalities of chromosomes. The technology is sensitive as well as specific, which does make it conducive to several types of genetic diagnoses.

• Fluorescent In-Situ Hybridization (FISH)

FISH does use fluorescent probes for identifying additional or missing chromosomes (such as trisomies) in the biopsied embryo cells, which are important for preimplantation genetic screening (PGS/PGT-A). It is capable of pinpointing chromosomal structural changes (inversions, translocations) or large-scale mutations in embryos, which are crucial for preimplantation genetic diagnosis (PGD).

By Application

• Chromosomal Abnormalities

The chromosomal abnormalities segment helps in the expansion of the preimplantation genetic testing market by identification of embryos with incorrect chromosome numbers, thereby reducing miscarriages, IVF failures, and birth defects. Modern preimplantation genetic testing is capable of detecting mosaicism (mix of abnormal/normal cells) and structural rearrangements (duplications, deletions), thereby offering a comprehensive screening and driving the clinical utility. Couples with failed IVF cycles or miscarriages switch to chromosomal screening, thereby expanding the base of the patient beyond the familiar genetic conditions.

• X-linked Diseases

The X-linked diseases segment does fuel the preimplantation genetic testing market by addressing generally untreatable conditions such as Hemophilia and Duchenne Muscular Dystrophy (DMD), thereby letting parents select unaffected carrier female embryos or male embryos, thereby averting transmission and raising demand for PGT-M (PGT for monogenic disorders). The advanced techniques such as next-generation sequencing (NGS) and enhanced PCR do improve precision for such single-gene tests, whereas the ability of testing sex-linked conditions does drive expansion of the market, especially in the regions with higher awareness or prevalence of these disorders.

• Embryo Testing

The embryo testing segment is boosting the preimplantation genetic testing market by helping in reducing risks of miscarriage/disability and raising demand through various technological advancements such as AI and NGS, thereby rendering testing safer (non-invasive PGT), accessible, and more precise. PGT does identify chromosomally normal (euploid) embryos, thereby raising rates of implantation and cutting down on multiple pregnancies by allowing single-embryo transfer.

• Aneuploidy Screening

The aneuploidy screening segment held the largest market share in 2024 (~25%), and the status quo is expected to remain unchanged during the forecast period. This is due to the increased adoption of aneuploidy screening and launching of novel products. In June 2024, Nxgen MDx introduced the Fetal RhD test, which operates on their existing Non-Invasive Prenatal Screen platform. Its non-invasive prenatal screening (NIPS) does assess for well-known abnormalities such as Down Syndrome (trisomy 21), trisomy 13, and trisomy 18.

• HLA Typing

The HLA typing segment accounts for the second-largest market share. This is driven by the use of preimplantation genetic testing for embryo HLA typing, especially for applications in stem cell therapy. This approach does improve the success of the hematopoietic stem cell transplantation by using genetically matched donors, which has been reported to enhance survival rates in comparison with the usage of unrelated donors.

By End-use

• Fertility Centers

Fertility centers are likely to emerge as a lucrative segment in the preimplantation genetic testing market during the forecast period. This is owing to the fact that such centers are specializing in assisted reproductive technologies, thereby offering preimplantation genetic testing for enhancing IVF procedures’ success rates by selecting the embryos that are genetically healthy. They also draw patients who are seeking advanced reproductive care, which is driving demand for preimplantation genetic testing services.

• Hospitals

The hospitals segment holds the largest market share, accounting for over 35% of the market share. This could be attributed to higher patient volume, improved healthcare infrastructure, and the availability of various IVF services in private and public hospitals. The couples who are seeking fertility treatments tend to choose hospitals owing to the technological advancements on their part. Plus, extensive research conducted in hospitals is expected to drive the testing rates within such settings.

• Diagnostic Centers

The diagnostic centers are home to sophisticated equipment (such as NGS) and skilled personnel, thereby allowing for complicated genetic analysis (PGT-SR, PGT-M, PGT-A) that the smaller clinics are unable to manage in-house. Their huge capacity lets them process several PGT tests in an efficient manner, which is important regarding rising demand and support extended to high-volume IVF cycles. The diagnostic labs are collaborating with fertility clinics and IVF centers, thereby turning out to be integral parts of the journey of the patient and enabling seamless integration of preimplantation genetic testing into the treatment plans.

• Research Centers & Academic Labs

Labs do conduct research and launch less invasive, safer methods such as non-invasive PGT (niPGT) (to analyze cell-free DNA from the culture media), which helps in boosting patients’ success rates and acceptance, thereby generating novel market opportunities. They do drive innovation in NGS (for higher levels of precision and throughput), AI integration (for quicker embryo assessment), and digital PCR, thereby rendering the tests more efficient.

Historical Context

The preimplantation genetic testing market is being driven by a decline in fertility rates at the global level coupled with clinical guidance that encourages euploid single-embryo transfer (SET). Non-invasive PGT, PGT bundling, and AI-enhanced embryo selection are the major opportunity areas in the market.

The preimplantation genetic testing (PGT) market’s ecosystem implies a network of key players inclusive of assay and reagent suppliers, software solution and instrument providers, and end-users such as specialized IVF centers and fertility clinics. Instruments and reagents facilitate embryo screening and advanced genetic analysis, whereas the digital tools do streamline data interpretation followed by reporting. IVF centers and fertility clinics do apply such technologies for selecting healthy embryos and minimizing genetic risks.

How is AI shaping the Preimplantation Genetic Testing Market?

AI algorithms are capable of conducting analysis of thousands of data points from the time-lapse videos and images of embryos for predicting their likelihood and viability of successful implantation with a higher level of precision as compared to human embryologists. There are tools such as the PGTai platform launched by CooperSurgical, which use AI for reducing noise in NGS data, thereby enhancing the reliability of aneuploidy detection. AI is one of the enablers in the development of non-invasive PGT (niPGT). The researchers, in place of embryo biopsy, are exploring the methods of analyzing cell-free DNA from culture media utilizing AI, so as to make the process less invasive and safer.

How are the U.S. Tariffs affecting Preimplantation Genetic Testing Market?

The U.S. tariffs are causing disruptions in the supply chain and raising operational costs regarding the preimplantation genetic testing market. Tariffs on imported consumables, lab equipment, reagents, and various other components increase procurement and production costs for preimplantation genetic testing (PGT) clinics and labs. The increased costs may partly be passed on to the patients, thereby rendering expensive procedures scarce. Also, the preimplantation genetic testing sector’s reliance on supply chains from Asia-Pacific and Europe translates into delayed delivery of the essential materials, thereby adversely affecting patient treatment schedules and clinical trial timelines.

Report Scope

Regional Perspective

The preimplantation genetic testing market is classified into North America, Europe, Asia Pacific, and LAMEA.

• North America

North America dominates the preimplantation genetic testing market and the scenario is expected to persist during the forecast period. This is reasoned with an increase in the prevalence of various disorders such as chlamydia and PCOS. Also, rising awareness about advancements regarding reproductive technology in the wake of increased infertility rates coupled with rising preference for customized medicine is catalyzing the preimplantation genetic testing market. The U.S. is at the forefront regarding supportive regulations and greater demand for IVF procedures.

• Asia Pacific

Asia Pacific is expected to witness the highest CAGR in the preimplantation genetic testing market due to advancements with regard to reproductive technology along with increased accessibility to healthcare. Japan and China are the major economies creating advancements in reproductive health. The higher rate of adoption of IVF does translate into greater usage of preimplantation genetic testing, along with rising awareness amongst the residents. India also houses regulatory bodies for monitoring challenges pertaining to reproductive health.

• Europe

Europe holds a significant market share. This is credited to increased number of IVF procedures due to later pregnancies. Numerous European economies are laying down regulations with respect to aneuploidy screening, along with presence of strong service providers, which are keeping the cash registers ringing. Also, the preimplantation genetic testing market in Germany and the U.K. is leading the market for Europe. Advantages of preimplantation genetic testing have encouraged more couples to go for genetic testing.

• LAMEA

The preimplantation genetic testing market is expected to grow on a substantial note during the forecast period. This is due to the entry of novel technologies and providers herein. The novel entrants table genomic methodologies and technologies that improve precision and expand the range of the conditions screened. Coming to MEA, Saudi Arabia and Kuwait are witnessing advancements in hereditary testing technologies, which improve the reliability, accuracy, and efficiency of the PGT procedures.

Key Developments

The preimplantation genetic testing market is witnessing a notable organic and inorganic expansion. Some of the key developments include –

• In September 2025, the market access team of Illumina announced that it had started focusing on expansion of non-invasive prenatal testing (NIPT) along with preimplantation genetic testing access in Abu Dhabi, UAE.

• In June 2025, Nucleus Genomics introduced Nucleus Embryo software in collaboration with Genomic Prediction, wherein it claims to cover 900 hereditary conditions.

• In April 2025, GeneDx completed the acquisition of fabric Genomics for close to US$ 51 Mn for facilitating AI-powered, decentralized genomic testing at the global level.

• In January 2024, Orchid Health announced that it had launched the first whole genome sequencing service at the commercial level for specific diseases in the preimplantation embryos.

Leading Players

The preimplantation genetic testing market is highly niche. Some of the key players in the market include:

• Quest Diagnostics Inc.
• Natera Inc.
• Cooper Surgical Inc.
• Genea Pty Limited
• Invitae Corporation
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Bioarray S.L.
• Illumina Inc.
• Igenomix
• RGI
• Hoffmann-La Roche AG
• Others

These firms apply numerous strategies to enter the market, including innovations and mergers and acquisitions, as well as collaboration. The agricultural robots market is shaped by the presence of diversified players that compete based on product innovation, vertical integration, and cost efficiency.

The Preimplantation Genetic Testing Market is segmented as follows:

By Procedure

• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis

By Product

• Reagents and Consumables
• Instruments
• Software

By Technology

• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescent In-Situ Hybridization (FISH)

By Application

• Chromosomal Abnormalities
• X-linked Diseases
• Embryo Testing
• Aneuploidy Screening
• HLA Typing

By End-use

• Fertility Centers
• Hospitals
• Diagnostic Centers
• Research Centers & Academic Labs

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America